adjuvant
News/ News/ News/ Oncology/ R&D
BMS’ plan to move Opdivo into adjuvant RCC gets knocked back
Phil Taylor
adjuvant, Bristol-Myers Squibb, immuno-oncology, Oncology, Opdivo, renal cell carcinoma
0 Comment
Roche’s Tecentriq extends lead over Keytruda in adjuvant NSCLC
Phil Taylor
adjuvant, immuno-oncology, Keytruda, Merck & Co, Non-small cell lung cancer, Oncology, regulatory approval, Roche, Tecentriq
0 Comment
Merck fights back against Roche in adjuvant lung cancer therapy
Phil Taylor
adjuvant, Keytruda, Merck & Co, Non-small cell lung cancer, Roche, Tecentriq
0 Comment
News/ News/ Sales and Marketing
GSK gets £1.4bn sales lift from COVID-19 products in 2021
Phil Taylor
adjuvant, COVID-19, Financial, GlaxoSmithKline, xevudy
0 Comment
Merck gets EU nod for Keytruda in adjuvant kidney cancer
Phil Taylor
adjuvant, EU, immuno-oncology, Keytruda, Merck & Co, Oncology, regulatory approval, renal cell carcinoma
0 Comment
Chasing Roche, Merck unveils adjuvant lung cancer data for Keytruda
Phil Taylor
adjuvant, Keytruda, Merck & Co, Non-small cell lung cancer, Roche, Tecentriq
0 Comment
NICE gives Keytruda parity with Opdivo for adjuvant melanoma
Phil Taylor
adjuvant, HEOR, melanoma, Merck & Co, NHS, NICE
0 Comment
Merck claims another adjuvant okay from FDA for Keytruda
Phil Taylor
adjuvant, fda, Keytruda, melanoma, Merck & Co, regulatory approval
0 Comment